Prevalence of hepatitis B markers in Senegalese HIV‐1‐infected patients

Authors:
Publisher website
Google Scholar
Abstract
The study aimed to estimate the prevalence of Hepatitis B virus (HBV) infection and to describe the HBV virological profiles among Senegalese HIV‐1‐infected patients. We conducted a retrospective study between 2006 and 2010 among Senegalese HIV‐1‐infected patients from the antiretroviral therapy cohort. Samples were screened using Determine® HBsAg or MONOLISA® POC test. The HBsAg positivity status was confirmed by Architect® HBsAg. Detection of HBeAg, anti‐HBe Ab, and HBV DNA load were done for the HBsAg‐positive samples. Then, Anti‐HBcAb was tested for the HBsAg‐negative samples. Microsoft Excel was used for data collection and statistical analyses were performed using Epi info 3.5.1. Overall, 466 HIV‐infected patients were enrolled including 271 women (58.4%), and 193 men (41.6%) with a median age of 39 years (19–74 years). The global prevalence of HIV/HBV coinfection (HBsAg positive) was 8.8% (41/466). For HBsAg positives samples, the prevalence of HBeAg and the anti‐HBeAb were, respectively, 24.4 and 69.2% and the median of HBV DNA viral load, for 27 HBsAg‐positive samples, was 3.75 log10 copies/ml. The virological profiles were the following: 7, 15, and 5 patients infected, respectively, by a replicative virus, an inactive virus and a probably mutant virus. For HBsAg‐negative samples, 83 out of 109 were positive for anti‐HBcAb. This study showed a significant decrease of the prevalence of HBV/HIV coinfection between 2004 and 2014 (P = 0.003), which highlighted the performance of the Senegalese HBV vaccine program. However, implementing a systematic quantification of HBV DNA viral load could improve the monitoring of HBV‐infected patient. J. Med. Virol. 88:461–465, 2016.

This publication has 22 references indexed in Scilit: